Eton Pharmaceuticals, Inc. (ETON)
61.27
-0.09
(-0.15%)
USD |
NASDAQ |
Nov 20, 14:13
Eton Pharmaceuticals Enterprise Value : 1.738B for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | 1.738B |
| November 18, 2026 | 1.756B |
| November 17, 2026 | 1.804B |
| November 16, 2026 | 1.810B |
| November 13, 2026 | 1.812B |
| November 12, 2026 | 1.740B |
| November 11, 2026 | 1.941B |
| November 10, 2026 | 1.916B |
| November 09, 2026 | 1.824B |
| November 06, 2026 | 1.596B |
| November 05, 2026 | 1.328B |
| November 04, 2026 | 1.431B |
| November 03, 2026 | 1.437B |
| November 02, 2026 | 1.433B |
| October 30, 2026 | 1.473B |
| October 29, 2026 | 1.516B |
| October 28, 2026 | 1.462B |
| October 27, 2026 | 1.444B |
| October 26, 2026 | 1.415B |
| October 23, 2026 | 1.410B |
| October 22, 2026 | 1.411B |
| October 21, 2026 | 1.390B |
| October 20, 2026 | 1.416B |
| October 19, 2026 | 1.388B |
| October 16, 2026 | 1.419B |
| Date | Value |
|---|---|
| October 15, 2026 | 1.448B |
| October 14, 2026 | 1.493B |
| October 13, 2026 | 1.506B |
| October 12, 2026 | 1.561B |
| October 09, 2026 | 1.560B |
| October 08, 2026 | 1.547B |
| October 07, 2026 | 1.551B |
| October 06, 2026 | 1.548B |
| October 05, 2026 | 1.572B |
| October 02, 2026 | 1.565B |
| October 01, 2026 | 1.467B |
| September 30, 2026 | 1.453B |
| September 29, 2026 | 1.677B |
| September 28, 2026 | 1.677B |
| September 25, 2026 | 1.634B |
| September 24, 2026 | 1.685B |
| September 23, 2026 | 1.576B |
| September 22, 2026 | 1.617B |
| September 21, 2026 | 1.567B |
| September 18, 2026 | 1.572B |
| September 17, 2026 | 1.617B |
| September 16, 2026 | 1.597B |
| September 15, 2026 | 1.556B |
| September 14, 2026 | 1.632B |
| September 11, 2026 | 1.617B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Aquestive Therapeutics, Inc. | 525.15M |
| Pfizer Inc. | 205.68B |
| Amneal Pharmaceuticals, Inc. | 10.67B |
| ANI Pharmaceuticals, Inc. | 1.754B |
| Corcept Therapeutics, Inc. | 6.745B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 35.25M |
| Revenue (Quarterly) | 57.92M |
| Total Expenses (Quarterly) | 22.68M |
| EPS Diluted (Quarterly) | 1.060 |
| Gross Profit Margin (Quarterly) | 76.48% |
| Profit Margin (Quarterly) | 60.85% |
| Earnings Yield | 2.46% |
| Operating Earnings Yield | 2.06% |
| Normalized Earnings Yield | 2.464 |